13 December 2024 - Benefit of treatment used in Crohn’s disease no longer demonstrated.

Data from a recent trial have shown that Alofisel, a cellular therapy used to treat complex anal fistulas in adults with Crohn’s disease, does not work well enough. The available data indicate that the benefit of Alofisel is no longer demonstrated and therefore it would not outweigh the risks associated with its use.

Read EMA press release